Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 15/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925453 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3938257 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3932633 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3928297 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3932630 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3932370 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3932374 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3938258 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3929774 | 1.00 | TLR4 (0.55) | TLR4MAPK1 | |
| SCHEMBL3929770 | 1.00 | TLR4 (0.55) | TLR4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541020-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-7063967-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| EP-0983286-B1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6764840-B2 | AUGMENT ANTIBODY PRODUCTION IN IMMUNIZED ANIMALS AS WELL AS STIMULATE CYTOKINE PRODUCTION AND ACTIVATE MACROPHAGES. | CORIXA CORPORATION | 2004-07-20 | — | — | US | disclosed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-1230250-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 60/4885MAPK1 1268/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 70/4885MAPK1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.